Email ID
Sign me in automatically next time
Merck Serono ditches cladribine, leaving MS franchise exposed

Merck Serono has finally given up on cladribine, its oral candidate for relapsing remitting multiple sclerosis. It has withdrawn the product from the approval process in the US and will...
22 June 2011
Eleanor Malone

Please Login to read the full article.
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36